Our Commitment to Patients
With Progesterone Receptor Positive (PR+) Cancers
At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer. To fulfill our promise to patients, we have created the ONWARD Clinical Trial network to evaluate our investigational product Apristor (onapristone ER).
Phase 2 Trial in ER+, PR+, HER2- Breast Cancer
ONWARD 201 will evaluate Apristor + Faslodex in second line (2L) metastatic breast cancer patients who are ER+, PR+, HER2- and who have failed first line Cdk4/6 inhibitor plus antiestrogen combination therapy.
ONWARD 203 / ONAWA
Window of Opportunity Trial in PR+ Breast Cancer
ONWARD 203 will evaluate Apristor in a presurgical, window of opportunity study in treatment naive PR+ breast cancer patients.
Phase 2 Basket Trial in PR+ Gynecologic Cancers
ONWARD 220 will evaluate Apristor in 2L/3L chemotherapy resistant uterine (endometrial) and ovarian (low grade serous, granulosa) cancer patients.
Investigator Sponsored Trials
Join our Investigator Network
At Context Therapeutics, we are committed to the advancement of medical and scientific knowledge that addresses the unmet needs of patients with hormone driven cancers.
Developing the next generation of antihormonal therapies to treat ovarian, endometrial, and breast cancers.
Apristor is an investigational new medicine for progesterone receptor positive (PR+) ovarian, endometrial, and breast cancers.